Cost-effectiveness of imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia

Cancer

Volumn 101, Issue 11, 2004, Pages 2574-2583

  Reed, Shelby D ^a,b   Anstrom, Kevin J ^a   Ludmer, Jennifer A ^a   Glendenning, G Alastair ^b   Schulman, Kevin A ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chronic myeloid leukemia; Clinical trials; Cost benefit analysis; Cytarabine; Interferon ; Survival analysis

Indexed keywords

ALPHA INTERFERON; CYTARABINE; IMATINIB;

ARTICLE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; HUMAN; LOW DRUG DOSE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COST-BENEFIT ANALYSIS; CYTARABINE; HEALTH CARE COSTS; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 8844262900     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20694     Document Type: Article

References (49)

1. Kalidas M, Kantarjian H, Talpaz M. Chronic myelogenous leukemia. JAMA. 2001;286:895-898.
2. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999;131:207-219.
3. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340.
4. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441-1446.
5. Cervantes F, Lopez-Guillermo A, Bosch F, Terol MJ, Rozman C, Montserrat E. An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia. Eur J Haematol. 1996;57:286-291.
6. Kantarjian HM, Shan J, Smith T, et al. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. Cancer. 2001;92:2501-2507.
7. Wadhwa J, Szydlo RM, Apperley JF, et al. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood. 2002;99:2304-2309.
8. Anger B, Carbonell F, Braunger I, et al. Blast crisis of Philadelphia chromosome-positive chronic myelocytic leukemia (CML): treatment results of 69 patients. Blut. 1988;57:131-137.
9. Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis: analysis of 242 patients. Am J Med. 1987;83:445-454.
10. Griesshammer M, Heinze B, Hellmann A, et al. Chronic myelogenous leukemia in blast crisis: retrospective analysis of prognostic factors in 90 patients. Ann Hematol. 1996;73:225-230.
11. Sacchi S, Kantarjian HM, O'Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999;86:2632-2641.
12. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;99:3547-3553.
13. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
14. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
15. Kantarjian HM, Talpaz M, O'Brien S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res. 2002;8:2177-2187.
16. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. N Engl J Med. 2003;348:994-1004.
17. Drummond MF. The use of health economic information by reimbursement authorities [review]. Rheumatology (Oxford). 2003;42 (Suppl 3):iii60-iii63.
18. Goldman J, Apperley J, Clark R, et al. Not so NICE for CML. Lancet. 2002;359:2036.
19. Pub L No. 108-173, 117 Stat 2066.
20. Baccarani M, Rosti G, de Vivo A, et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood. 2002;99:1527-1535.
21. Kantarjian HM, O'Brien S, Cortes JE, et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003;97:1033-1041.
22. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med. 1995;122:254-261.
23. Kloke O, Niederle N, Opalka B, Hawig I, Seeber S, Becher R. Prognostic impact of interferon alpha-induced cytogenetic remission in chronic myelogenous leukaemia: long-term follow-up. Eur J Haematol. 1996;56:78-81.
24. Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001;98:3074-3081.
25. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. Blood. 1998;92:1541-1548.
26. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997;337:223-229.
27. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815-2834.
28. Anstrom KJ, Reed SD, Allen AS, Glendenning GA, Schulman KA. Long-term survival estimates for imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2004;101:2584-2592.
29. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539.
30. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095-1108.
31. Stinnett AA, Paltiel AD. Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means. Med Decis Making. 1997;17:483-489.
32. Kattan MW, Inoue Y, Giles FJ, et al. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med. 1996;125:541-548.
33. Messori A. Cost-effectiveness of interferon in chronic myeloid leukaemia: analysis of four clinical studies. Ann Oncol. 1998;9:389-396.
34. Liberato NL, Quaglini S, Barosi G. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia. J Clin Oncol. 1997;15:2673-2682.
35. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332:1418-1424.
36. Kantarjian H, O'Brien S, Cortes J, et al. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin Cancer Res. 2004:10(1 Pt 1):68-75.
37. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63:789-799.
38. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998;90:850-858.
39. Beck JR, Guilhot J, Giles FJ, Aoki N, Wirt DP, Guilhot F. Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia. Leuk Lymphoma. 2001;41:117-124.
40. Kantarjian HM, Cortes JE, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003;101:97-100.
41. Ricci C, Scappini B, Divoky V, et al. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer Res. 2002;62:5995-5998.
42. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003;101:473-475.
43. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2:117-125.
44. Druker BJ. Imatinib alone and in combination for chronic myeloid leukemia. Semin Hematol. 2003;40:50-58.
45. La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res. 2002;62:7149-7153.
46. Tipping AJ, Mahon FX, Zafirides G, Lagarde V, Goldman JM, Melo JV. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia. 2002;16:2349-2357.
47. La Rosee P, O'Dwyer ME, Druker BJ. Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia. 2002;16:1213-1219.
48. Axdorph U, Stenke L, Grimfors G, et al. Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase: a report from the Swedish CML Group. Br J Haematol. 2002;118:1048-1054.
49. [No authors.] 2000 Drug topics red book. Montvale, NJ: Medical Economics Co., 2000.